Systemic lupus erythematosus (SLE) is an autoimmune disease with causes including activation of innate and adaptive immune systems. SLE patients are with a high risk of thrombosis, which may be due to disease activation, immune complexes, toxic antibodies and high level of inflammation. This article discusses neutrophil/NET factor, antibody factor, platelet factor and particle factor which is involved in coagulation pathways and thrombus formation mechanism under the state of immune disorders in SLE.
Blood Coagulation ; Blood Coagulation Factors ; Humans ; Lupus Erythematosus, Systemic ; immunology ; Thrombophilia ; immunology ; Thrombosis

Since heparin is an anticoagulant commonly used in hemodialysis and the patients on hemodialysis are repeatedly exposed to heparin, heparin may be the cause of the development of heparin-dependent antibodies and thrombotic complications in patients on hemodialysis. The purpose of this study was to determine the prevalence and the clinical significance of the antibodies against heparin-platelet factor 4 complexes as determined by enzyme immunoassay in patients on maintenance hemodialysis. The prevalence of anti-heparin-platelet factor 4 antibodies was higher in hemodialysis patients than in normal subjects (8.8 vs 0.0%, p<0.05). The number of past episodes of vascular access obstruction per year was significantly higher in the anti-heparin-platelet factor 4 antibody positive group than antibody negative group. Anti-heparin-platelet factor 4 antibody positive patients experienced more frequent vascular access obstructions than control subjects. In conclusion, anti-heparin-platelet factor 4 antibody might be a risk factor for vascular access obstructions in patients with end-stage renal disease on maintenance hemodialysis.
Adult ; Autoantibodies/immunology* ; Autoimmune Diseases/immunology* ; Catheters, Indwelling* ; Enzyme-Linked Immunosorbent Assay ; Female ; Heparin/immunology* ; Human ; Kidney Failure, Chronic/blood ; Kidney Failure, Chronic/immunology ; Kidney Failure, Chronic/therapy* ; Male ; Middle Aged ; Platelet Factor 4/immunology* ; Recurrence ; Renal Dialysis* ; Risk Factors ; Thrombophilia/immunology* ; Thrombosis/epidemiology* ; Thrombosis/immunology ; Thrombosis/prevention & control